Pharmaceutics and Novel Drug Delivery Systems

Marina Slavsky has completed her M.S. from Moscow State University of Fine Chemical Technologies, Russia. She is the senior scientist in AstraZeneca DMPK group. Marina has extensive experience in high throughput assay development, automation, validation, and implementation for drug discovery and development.

Professor Dr. Heyam Saad Ali, She used to work as a head of pharmaceutics department in Dubai Pharmacy College, UAE. Currently, she is working in University of Khartoum, Faculty of Pharmacy, Pharmaceutics Department, Prof. contributed more than 70 articles to reputed international scientific journals and invited as speaker in many conferences. The subjects of interest include: different types of conventional, controlled and targeted drug delivery systems in nanotechnology, pharmaceutical product development, Quality control, Quality assurance and GMP in pharmaceutical industry. She has been invited as speaker to numerous International conferences. In, addition of being Editor, Reviewer and member of editorial board of many international journals

Dr. Qingyu Zeng has 25 years of extensive working experience. Throughout his career, Qingyu has served in various roles such as fellow, technical director, and advanced technology platform leader with various responsibilities to strategically lead many multi discipline team efforts to identify, evaluate, and develop cutting-edge products and core technologies for successful commercial platform deployment. He holds more than 10 granted patents. Qingyu graduated with BS and MS from Donghua University in China, received his Ph.D. in Polymer Science from North Carolina State University, and completed his EMBA from Ohio State University.

Prachi V. Atre has completed her Master’s in Industrial Pharmacy Practice from St.John’s University, Queens, NY, 11439. She has 3+ years of experience in injectables and is currently working as a Formulation Scientist II at Nexus Pharmaceuticals, Inc. She has published poster abstracts and presentations at Annual Meetings and Expositions such as American Asociation of Pharmaceutical Scientists (AAPS) and Controlled Release Society (CRS). She has good written and communication skills and has published review article on injectables recently.

Iris Valtingojer is a group leader in the Molecular Oncology Research Department from Sanofi, France. Her professional experience lies in the leadership of small molecule drug discovery projects in a precision medicine context. Over the past 10 years she has taken multiple projects from target identification up to development candidate selection. Iris’ research team focuses on new and innovative pathways for cancer therapy and the identification of targets and drugs in this context. She joined Sanofi as a Post-Doc in Biochemistry and holds a Ph.D. from the Max-Planck Institute in Cologne, Germany, as well as a Master degree in Biology and Biochemistry from the University of Vienna, Austria.

Souvik Basak, age 39 years, has completed his B.Pharm. and M.Pharm from Jadavpur University, Kolkata, India (2004 and 2006 respectively) and accomplished his PhD from Nanyang Technological University, Singapore at 2013. He has been working as Associate Professor, Division of Pharmaceutical Chemistry in Dr. B.C. Roy College of Pharmacy & Allied Health Sciences, Durgapur, WB, India since 2018. He has published more than 30 papers in various international journals of repute, several book chapters and more than 50 conference proceedings/presentations. He has published one Indian patent and associated as research consultant with various international research farms and Professors. He is currently also a member of fellow of Institute of Chemist, India

Swietnicki is a scientist working on antibacterial strategies. The work is focused on novel vaccines and therapeutics targeting bacterial virulence systems. Dr. Swietnicki obtained his Ph.D. in Biochemistry and Molecular Biology from the University of Florida, Gainesville, FL, USA, in 1995 for his work on Hepatitis A Virus 3C protease. Later he worked on human prion proteins at CWRU, Cleveland, OH, USA before starting work on Select Agents at USAMRIID, Ft. Detrick, MD, USA, and ECBC, APG, MD, USA. In 2011 he moved to Poland to work on virulence blockers of enteropathogenic E. coli at EIT+ and later on novel vaccines against periodontitis at the Institute of Immunology and Experimental Therapy of PAS in Wroclaw, PL.

Dr. Blondino has over 20 years of broad based drug development experience in parenteral, oral liquid, and inhalation products. He is currently the Director of Drug Development at Kaleo, Inc. in Richmond, Virginia. He has held industrial positions

Wen Shuai is currently a postgraduate in the Department of Medicinal Chemistry at China Pharmaceutical University (Nanjing, China). Her research focus on the design and synthesis of novel microtubule-inhibitor agents and novel tyrosinase inhibitors, which has published 8 peer-reviewed journal articles. She is passionate about acquiring the latest advances in medicinal chemistry via various medicinal chemistry conferences.

Abdul Mannan Fateh currently studying Ph.D. student (last year) in pharmacology department in the faculty of medicine in University Malaya in Malaysia. He has completed his Master degree (M.SC.) in toxicology. DEP. Medical sedimentology & toxicology, Hamdard university (new – Delhi) India. He has worked in medical college from 2008 –2013 in Yemen as a lecturer in Toxicology. He has published 4 Research Publications in well-reputed ISI journals Q1&Q2 and high impact factor. Participant in two international conferences at Oslo, Norway & Malaysia.